Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients

  The majority of patients with type 1 diabetes who were treated with dapagliflozin, a sodium glucose cotransporter-2 inhibitor (SGLT-2) used to treat type 2 diabetes, had a significant decline in their blood sugar levels, according to a new study published in The Lancet Diabetes and Endocrinology. The results were presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Lisbon. DEPICT-1 (Dapagliflozin in Patients with Inadequately Controlled Type 1 diabetes) is a 24-week study and was the first global multicenter investigation of dapagliflozin to test its efficacy and safety in type 1 diabetes. The double-blind, randomised, three-arm,